Langerhans' cell histiocytosis (LCH) is characterized by an accumulation and/or proliferation of cells with a Langerhans' cell (LC) phenotype. The aetiology and pathogenesis of LCH are unknown; it is suggested that LCH is caused by an immunological dysregulation. Production of cytokines is a central
Langerhans cell histiocytosis: coexistence of bronchogenic and thymic cysts in the thymus
β Scribed by Ryoji Kawano; Enjo Hata; Shingo Ikeda; Toshiya Yokota; Kohei Tagawa; Fumitomo Sato
- Book ID
- 107497458
- Publisher
- Springer Japan
- Year
- 2008
- Tongue
- Japanese
- Weight
- 209 KB
- Volume
- 56
- Category
- Article
- ISSN
- 1863-6705
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Twentyβtwo patients with Langerhans cell histiocytosis (LCH) were managed in the UCLA Department of Radiation Oncology from 1974 to 1987. Their median age was 17 years (range 1β42 years) and median followup 4.5 years (range 1β13 years). Fourteen patients had disease localized to a bone
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.